This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: BRF, Hewlett Packard, Luckin Coffee, Cronos Group and Pure Storage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BRF, Hewlett Packard, Luckin Coffee, Cronos Group and Pure Storage
5 Top-Ranked Cheap Stocks Trading Under $20 to Buy Right Now
by Benjamin Rains
Today we found 5 cheap stocks currently trading for under $20 per share using our Zacks Stock Screener that investors might want to buy heading into November...
Will Pricing be an Upside for Altria (MO) in Q3 Earnings?
by Zacks Equity Research
Gains from pricing and savings efforts are likely to be reflected on Altria's (MO) Q3 results. However, receding cigarette sales volumes are a concern.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $7.85 in the latest trading session, marking a -1.32% move from the prior day.
Stocks Jump on Trump Trade Tweet, Q3 Earnings and Buy Marijuana Stocks - Free Lunch
by Benjamin Rains
U.S.-China trade war updates, including President Trump's tweet that helped U.S. stocks climb Thursday. A look at the ongoing fight between the NBA and China, some Q3 earnings results next week, and why marijuana stock Cronos looks like a buy - Free Lunch
Stocks Fall on U.S. Blacklist, China & the NBA and Buy Roku - Free Lunch
by Benjamin Rains
A look at the new U.S. blacklist on nearly 30 Chinese companies and how it might impact the upcoming trade talks. A dive into the dispute between the NBA and China, marijuana stocks, and why Roku is a Zacks Rank #1 (Strong Buy) - Free Lunch
Cronos Group (CRON) Stock Moves -0.99%: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed the most recent trading day at $8.96, moving -0.99% from the previous trading session.
Is Constellation Brands (STZ) Stock a Buy Heading into Q2 Earnings?
by Benjamin Rains
Should investors consider buying shares of Constellation Brands (STZ) as we head into the release of its second quarter fiscal 2020 earnings results, due out on Thursday, October 3?
Epidolex Progresses: Will the Marijuana Drug Market Boom?
by Indrajit Bandyopadhyay
Cannabis (or marijuana) based medical products have the potential to become the next booming industry.
GW Pharma Gets EU Nod for Anti-Epileptic Drug Epidyolex
by Zacks Equity Research
GW Pharmaceuticals (GWPH) wins EU approval for Epidyolex as an adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients aged two years and above.
Cannabis Industry to Scale New Highs Amid Legalization Woes
by Nilanjan Gupta
Legalization will likely drive commercial distribution of cannabis and boost growth of companies operating in this space.
Can Altria Battle Dwindling Cigarette Sales & Vaping Worries?
by Zacks Equity Research
Altria (MO) is reeling under regulatory pressures in the tobacco industry. However, higher pricing is likely to provide support.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed the most recent trading day at $10.96, moving -1.7% from the previous trading session.
Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility?
by Benjamin Rains
Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?
Altria (MO) in Talks to Unite With Philip Morris, Stock Down
by Zacks Equity Research
Altria (MO) is in discussions with Philip Morris to consider the prospects of a merger. The companies have not revealed further information regarding the development.
Altria and Phillip Morris International in Merger Talks: What you Need to Know
by Mitchell Moore
On Tuesday, tobacco giants Altria (MO) and Philip Morris International (PM) announced discussions of a possible merger. The two companies stated that a deal has not yet been reached, but that it is possible and talks are underway.
Canopy Growth (CGC) Earnings After The Bell: How High Can They Go?
by Daniel Laboe
Canopy is the clear leader in the marijuana space with a vastly diversified portfolio of cannabis products along with its STZ partnership.
ETFs in Focus as Consolidation Drives Marijuana Industry
by Sanghamitra Saha
Deals activity has been robust in the marijuana space, paving way for gains in these cannabis ETFs.
Has Cronos Group (CRON) Outpaced Other Finance Stocks This Year?
by Zacks Equity Research
Is (CRON) Outperforming Other Finance Stocks This Year?
Cronos Group (CRON) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 50.00% and 35.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.
Cronos Group (CRON) Stock Moves -0.79%: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed the most recent trading day at $13.81, moving -0.79% from the previous trading session.
Marijuana & Blockchain ETFs: Should You Buy?
by Neena Mishra
Cannabis and blockchain are high-risk, high-reward areas of the market. Should investors consider these ETFs?
What to Expect from Altria Earnings as MO Stock Continues to Struggle
by Mitchell Moore
Altria Group (MO) stock is up just 1.5% so far in 2019 to lag behind the tobacco market's nearly 16% climb. Let's see if we should expect this underperformance to continue following the release of Altria's earnings report before the market opens on Tuesday, July 30, or might MO shares get a boost.
Cronos Group (CRON) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $15.43 in the latest trading session, marking a +0.39% move from the prior day.